Royalty Report: Drugs, Disease, Therapeutic – Collection: 257486

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 11

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Cancer
  • Pain
  • Technical Know How
  • Delivery
  • Pharmaceuticals
  • Diagnostic
  • Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 257486

License Grant
The Swiss Licensor grants an Exclusive sublicense in the Field under the Patents, to the extent, but only to the extent, that such patents or patent applications claim the Compound or Product or the manufacture, formulation, or use thereof, and Know-How to develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the Territory, subject to the terms and conditions of this Sublicense Agreement.

Licensor grants a non-exclusive, worldwide sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product which may be claimed in Patents limited solely to making or using the Compound or Product.

Licensee represents and warrants that during the term of this Sub license Agreement, neither it, an Affiliate or a Sublicensee shall license, develop, have developed, manufacture, have manufactured, sell or have sold any of the following compounds or products classified as an atypical antipsychotic: i.e. Olanzapine, Sertindole, Seroquel, Ziprasadone, Risperidone.

License Property
Licensor has rights to certain patents and patent applications, and know-how relating to a compound known as Iloperidone.

Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is 1 -[ 4-(3-[ 4-(6-fluoro-l ,2-benzisoxazol-3-y 1)-1-piperidinyl]propoxy ]-3-methoxyphcnyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed hereto, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Field of Use
The Field shall mean application to all conditions, disorders and diseases in humans.  The licensed property use is for therapeutic treatment of schizophrenic patients.

IPSCIO Record ID: 257485

License Grant
The Licensor of Switzerland and the Licensee now desire to modify their arrangements under the Original Agreement to provide, among other things, for the relinquishment of the sublicenses and licenses granted by Licensor to Licensee under the Original Agreement in the U .S./Canadian Territory, for the grant by Licensee to Licensor of exclusive license rights with respect to certain Licensee Know-How and Licensee Trademarks and for the assignment by Licensee to Licensor of the Existing Applications and Approvals and the Licensee Domain Names.

The Swiss Licensor grants an Exclusive sublicense in the Field under the Patents licensed to Licensor or its Affiliates and an Exclusive license in the Field under the Patents, except for the Biomarker Patent, owned by Licensor or its Affiliates,  an Exclusive sublicense and license, as applicable, in the Field under the Know-How and a non-exclusive license in the Field under the Patent owned by Licensor covering the biomarker, in each case, to research, develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the ROW Territory,

Licensor grants a non-exclusive, ROW Territory sublicense to make or use any analytical reference standards, intermediate or metabolite of the Compound or Product, not listed, which may be claimed in Patents in the ROW Territory limited solely to making or using the Compound or Product.

License Property
Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is I-[ 4-[3 -[ 4-( 6-fluoro-1,2-benzisoxazol-3-y 1 )-1-piperidiny l] propoxy]-3-methoxyphenyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Product shall mean any bulk or finished pharmaceutical composition containing the Compound as a pharmaceutically active ingredient for use in the Field.

Depot Formulation shall mean any extended-release, injectable formulation of the Compound.

The parties acknowledge and agree that Products sold within the United States will be sold only under the  trademark FANAPTâ„¢.

Field of Use
Field shall mean application to all conditions, disorders and diseases in humans.  The licensed patents field of use is as antipsychotic drugs.

IPSCIO Record ID: 257706

License Grant
The Licensee of Switzerland and the Licensor now desire to modify their arrangements under the Original Agreement to provide, among other things, for the relinquishment of the sublicenses and licenses granted by Licensee to Licensor under the Original Agreement in the U .S./Canadian Territory, for the grant by Licensor to Licensee of exclusive license rights with respect to certain Licensee Know-How and Licensee Trademarks and for the assignment by Licensor to Licensee of the Existing Applications and Approvals and the Licensee Domain Names.

Licensor grants the Swiss Licensee an Exclusive license in the Field under the Licensor Know-How to research, develop, have developed, make, have made, use, import, sell, offer for sale and have sold the Compound and Product in the U.S./Canadian Territory.

Licensor grants an exclusive right and license, with the right to grant sublicenses, to use the Licensor Trademark in the U.S./Canadian Territory in connection with the manufacture, use, import and commercialization of Products in the U.S./Canadian Territory;  and, a nonexclusive license to use the Licensor Trademarks, other than the Licensed Trademark in the U.S./Canadian Territory in connection with the manufacture and commercialization of Products, such license to include the right to distribute Products in the U.S./Canadian Territory with packaging that bears the Licensor Trademarks; and an exclusive right and license, with the right to grant sublicenses, to use the Licensor Copyrights in connection with the commercialization of the Products in the U.S./Canadian Territory.

License Property
Compound shall mean the chemical compound known as Iloperidone, whose specific chemical name is I-[ 4-[3 -[ 4-( 6-fluoro-1,2-benzisoxazol-3-y 1 )-1-piperidiny l] propoxy]-3-methoxyphenyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites listed, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Product shall mean any bulk or finished pharmaceutical composition containing the Compound as a pharmaceutically active ingredient for use in the Field.

Depot Formulation shall mean any extended-release, injectable formulation of the Compound.

The trademark and domain names all relate to FANAPTâ„¢ and Iloperidone.

Iloperidone, commonly known as Fanapt and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.

Field of Use
The licensed patents field of use is as antipsychotic drugs.

IPSCIO Record ID: 166962

License Grant
Licensor grants an exclusive license in the field under the patents and know-how to develop, have developed, make, have made, use, import, sell, offer for sale and have sold Compound and Product in the Territory.

Licensor grants a non-exclusive, worldwide license to make or use any analytical reference standards, intermediate or metabolite of Compound or Product not listed hereto which may be claimed.

License Property
Licensor is the owner of all right, title and interest in certain patents and patent applications and know-how relating to the chemical compound known as Iloperidone.

Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.

Field of Use
The field shall mean the treatment in humans of psychiatric disorders, psychotic disorders and analgesia.

IPSCIO Record ID: 223128

License Grant
The Swiss Licensors hereby grant to Licensee an exclusive license, with the right to sublicense with the prior written consent of Licensors, such consent not to be unreasonably withheld, under the Licensor Patents and Licensor Know-How, to develop, use, make and have made Compound and Product in the Field of Use and in the Territory.
License Property
Product shall mean a formulated pharmaceutical product containing the Compound or Back-up Compound as an active ingredient and packaged for the use by the ultimate consumer.

Compound shall mean the compound currently identified by Licensors as NDD-094 or isomers or epimers thereof and any metabolites and salts thereof and more particularly described Licensor Patents shall mean those Patents Controlled by Licensor claiming Compound, Product, or their metabolites or any formulation of Compound, processes, uses and intermediates of the foregoing.

Licensor Know-How shall mean any proprietary or nonproprietary information specific to the Compound or Product within the Field of Use and of a confidential nature necessary or useful for the manufacture, preparation or development of the Compound or Product Controlled by Licensors during the term of this Agreement and shall include, without limitation, data, knowledge and information., including chemical, stability, pharmacological, toxicological, pre-clinical, clinical and manufacturing data, samples, documentation, analytical standards, and gene expression data.

Patents – United States
5,635,521 – Imidazolylmethyl-pyridines
5,856,343 – Imidazolylmethyl-pyridines used for senile dementia

Field of Use
This agreement pertains to the drug industry relating to the Field of Use that shall mean application to all conditions, disorders and diseases in humans.

Iloperidone is an atypical antipsychotic for the treatment of schizophrenia.

IPSCIO Record ID: 52353

License Grant
Pursuant to a Worldwide License Agreement,  and that certain Iloperidone Sublicense Agreement, this agreement addresses current compensation for the License Agreement.  The original agreement grants an exclusive license in the field under the patents and know-how to develop, have developed, make, have made, use, import, sell, offer for sale and have sold compound and product in the territory.
License Property
Licensor is the owner of all right, title and interest in certain patents and patent applications, and know-how relating to a compound known as Iloperidone, whose more specific chemical name is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanone, including any salts, hydrates, solvates, and/or stereoisomers thereof, and only the metabolites hereto, including any salts, hydrates, solvates and/or stereoisomers of such metabolites.

Patents include:
US –  07/354,411  abandoned;  US –  07/456,790  abandoned;  EP –  90/09208.0,  granted    0 402 644 B1;  Austria –  55770/90,  issued   640,653;  Canada –  2,017,193-6;  China –  90103721.4;  Czech Republic   –   2425-90;  Finland –  902449;  Hungary – 3090/90;  Israel  –  94425;  Japan – 127090/90,  issued  1931594;  Korea  –  90/7102;  Mexico –  20787;  Norway  –  P902214, 177301;  Philippines  –  40530;  Poland –  P-285247,  163965;  Russia –  4743876/04;  US – 07/619,825  continuation   abandoned;  US – 07/944,705  continuation   abandoned;  US –  07/788,269  abandoned;  US –  07/969,383  issued  5,364,866;  PCT –  92/09276   WO/93/09102;  EP –  92/924151.1;  EP (PT)  –  92/118992.5; Austria –  30570/92;  Belarus  – 1715;  Canada –  2,121,253; Czech Republic  – PV 1102-94; Finland –  942052; Georgia –  001977; Hungary –  P9401316; Israel  – 103622; Japan –  5-508591; Korea  –  94-701524; Kazakhstan – 941593.1; Mexico –  926370; Norway – 941647; New Zealand  –  245006; Philippines  –  45259; Poland – P-303452; Romania – 9400761;  Russia – 94028105.04; Slovak Republic  –   PV 0456-94; Taiwan – 81108831; Uzbekistan  –  9500706.1; US  – 08/144,265   abandoned; US – 08/309,395  pending; US –  08/329,000  allowed; US – 08/468,611  pending; PCT – 94/12054    WO95/11680; Canada –  94/12054; China –  94194302.X; Czech Republic   –   PV 1238-96; Hungary –  P/P 00576     06/29/95,  211,853    11/05/95     06/29/2015; Indonesia – 951058; Ireland – 94/12054; Israel – 111,498; Japan – 512724/1995; Korea – 96-702162; Mexico – 94 8405;Norway –  p961686; New Zealand – 275941; Poland  –  P314135; Romania – 96-00888; Russia  –  96110214; Taiwan  –  83110396; South Africa  –  95/2653

Field of Use
The field is the treatment in humans of psychiatric disorders, psychotic disorders and analgesia.

IPSCIO Record ID: 182112

License Grant
Licensor hereby grants to Licensee perpetual, irrevocable worldwide, royalty-bearing right and license under the Licensor Technology to research, Develop, manufacture, have manufactured, use and Commercialize the Licensed Products in and for the Field.
License Property
This program is for a TR Beta.  Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines

“TR-Beta Compounds” means Metabasis’ MB07811 and MB10866 compounds, and any other compounds comprised by the TR-Beta Patents, and any salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers, polymorphs, and derivatives of such compounds.

Field of Use
“Field” means all therapeutic and diagnostic uses in humans or animals.

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.

IPSCIO Record ID: 182114

License Grant
The Company entered into an agreement to license the rights to Licensor DGAT-1 programs.
License Property
“DGAT-1 Compounds” means Metabasis’ MB11210 compound, and any other compounds comprised by the DGAT-1 Patents, and any salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers, polymorphs, and derivatives of such compounds.

Diacylglycerol O-acyltransferase 1 is an enzyme that in humans is encoded by the DGAT1 gene.

Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.

Field of Use
The portfolio of orally available small molecule inhibitors of the enzyme DGAT-1 for the potential treatment of lipid disorders such as obesity and dyslipidemia.

IPSCIO Record ID: 275417

License Grant
Licensor grants the Licensee of Italy:
—   an exclusive license, with the right to grant sublicenses, under Licensor’s right, title and interest in and to the Licensor Patents, the Licensor Know-How, the Joint IP, the Joint Patents and the New IP owned or Controlled by Licensor specifically for and limited to Develop the Product in the Licensee Territory for the Indication, and
—  an exclusive license, with the right to grant sublicenses, under Licensor’s right, title and interest in and to the Licensor Patents, the Licensor Know-How, the Joint IP, the Joint Patents and the New IP owned or Controlled by Licensor to Manufacture, have Manufactured and Commercialize the Product in the Licensee Territory for the Indication.
License Property
Compound means Licensor’s proprietary molecule known as Brilacidin, including any back-up compounds and analogues (including, prodrugs, metabolites, complexes, degradants, impurities, mixtures and other combinations) their salts, solvates, hydrates, stereoisomers, crystalline and amorphous forms, owned or Controlled by Licensor as of the Effective Date or during the Term.
Field of Use
The filed of use is for the prevention, treatment, amelioration, diagnosis or monitoring of Ulcerative Proctitis/Proctosigmoiditis (UP/UPS) using finished formulation(s) for local administration (e.g., gel, foam, enema) to the rectum and/or colon.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.